Exelixis is an oncology-focused biotechnology company striving to accelerate discovery, development, and commercialization of new products for difficult-to-treat cancers. Clinical development focuses on continued evaluation of approved products and investigational pipeline. Exelixis continues to invest in expansion of our product pipeline through internal drug discovery and strategic business development opportunities.